Skip to main content

Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.

Publication ,  Journal Article
Coeytaux, RR; Schmit, KM; Kraft, BD; Kosinski, AS; Mingo, AM; Vann, LM; Gilstrap, DL; Hargett, CW; Heidenfelder, B; Dolor, RJ; McCrory, DC
Published in: Chest
May 2014

BACKGROUND: Current treatments for pulmonary arterial hypertension (PAH) have been shown to improve dyspnea, 6-min walk distance (6MWD), and pulmonary hemodynamics, but few studies were designed to compare treatment regimens or assess the impact of treatment on mortality. METHODS: We conducted a systematic review to evaluate the comparative effectiveness and safety of monotherapy or combination therapy for PAH using endothelin receptor antagonists, phosphodiesterase inhibitors, or prostanoids. We searched English-language publications of comparative studies that reported intermediate or long-term outcomes associated with drug therapy for PAH. Two investigators abstracted data and rated study quality and applicability. RESULTS: We identified 28 randomized controlled trials involving 3,613 patients. We found no studies that randomized treatment-naive patients to monotherapy vs combination therapy. There was insufficient statistical power to detect a mortality difference associated with treatment. All drug classes demonstrated increases in 6MWD when compared with placebo, and combination therapy showed improved 6MWD compared with monotherapy. For hospitalization, the OR was lower in patients taking endothelin receptor antagonists or phosphodiesterase-5 inhibitors compared with placebo (OR, 0.34 and 0.48, respectively). CONCLUSIONS: Although no studies were powered to detect a mortality reduction, monotherapy was associated with improved 6MWD and reduced hospitalization rates. Our findings also suggest an improvement in 6MWD when a second drug is added to monotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

May 2014

Volume

145

Issue

5

Start / End Page

1055 / 1063

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Respiratory System
  • Pulmonary Wedge Pressure
  • Prostaglandins
  • Phosphodiesterase 5 Inhibitors
  • Hypertension, Pulmonary
  • Humans
  • Global Health
  • Familial Primary Pulmonary Hypertension
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Coeytaux, R. R., Schmit, K. M., Kraft, B. D., Kosinski, A. S., Mingo, A. M., Vann, L. M., … McCrory, D. C. (2014). Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest, 145(5), 1055–1063. https://doi.org/10.1378/chest.13-1864
Coeytaux, Remy R., Kristine M. Schmit, Bryan D. Kraft, Andrzej S. Kosinski, Alicea M. Mingo, Lisa M. Vann, Daniel L. Gilstrap, et al. “Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.Chest 145, no. 5 (May 2014): 1055–63. https://doi.org/10.1378/chest.13-1864.
Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014 May;145(5):1055–63.
Coeytaux, Remy R., et al. “Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.Chest, vol. 145, no. 5, May 2014, pp. 1055–63. Pubmed, doi:10.1378/chest.13-1864.
Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, Gilstrap DL, Hargett CW, Heidenfelder B, Dolor RJ, McCrory DC. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014 May;145(5):1055–1063.

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

May 2014

Volume

145

Issue

5

Start / End Page

1055 / 1063

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Respiratory System
  • Pulmonary Wedge Pressure
  • Prostaglandins
  • Phosphodiesterase 5 Inhibitors
  • Hypertension, Pulmonary
  • Humans
  • Global Health
  • Familial Primary Pulmonary Hypertension